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COMMENTARY Open Access
Promoting public access to clinical trial
protocols: challenges and
recommendations
An-Wen Chan1,2* and Asbjørn Hróbjartsson3,4
Abstract
Background: Recognizing the value of promoting public access to clinical trial protocols, Trials pioneered the way
for their publication over a decade ago. However, despite major advances in the public accessibility of information
about trial methods and results, protocol sharing remains relatively rare.
Main body: Protocol sharing facilitates the critical appraisal of clinical trials and helps to identify and deter the selective
reporting of outcomes and analyses. Challenges to the routine availability of high quality trial protocols include the gaps
in incentives and adherence mechanisms, limited venues for sharing the original and final protocol versions, and the
need for mechanisms to ensure transparent and complete protocol content.
Conclusions: We propose recommendations for addressing key challenges to protocol sharing in order to promote
routine public access to protocols for the benefit of patients and other users of evidence from clinical trials.
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Introduction
As the cornerstone of medical evidence, clinical trials have
been instrumental to major healthcare advances over the
past decades. However, the impact and value of clinical
trials have been limited by inaccessible or selectively
reported information about their methods and results,
leading to substantial research waste with direct implica-
tions for healthcare costs and patient outcomes [1].
Public access to study protocols is fundamental to the so-
cietal value of clinical trials. The trial protocol is the core
document reporting the study background, relevance,
methods, administration, and ethical considerations [2].
The protocol guides the study team to help ensure that the
trial is implemented in a manner that is consistent with the
research objectives and the intentions of the steering group.
Prior to recruiting study participants, the protocol serves as
the basis for trial registration and for external review by
research ethics committees and regulators. Increasingly, the
protocol is also reviewed after trial completion to place its
results into proper context.
In 2006, Trials pioneered the way for public access to
trial protocols by providing a venue for their publication
[3]. Over 10 years later, the value of public access has
become generally accepted by trialists, sponsors, funders,
journal editors, regulators, healthcare providers, and
patients. This acceptance has manifested in the growing
number of protocols made available in journals as stand-
alone publications or as web supplements accompanying
published final reports [4]. In Trials alone, the number
of published protocols has increased from 46 in 2008 to
167 in 2012 and 359 in 2016.
However, despite repeated calls for increased protocol
sharing [5–7], most clinical trials do not have a publicly
accessible protocol [8–10]. In this commentary we
review the rationale and challenges, and propose recom-
mendations for improving public access to protocols.
Benefits of protocol sharing
Public availability of study protocols helps to facilitate
detailed assessments of the internal validity of a trial,
deter selective reporting of outcomes and analyses, and
improve understanding of external validity. This key role
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is becoming even more relevant with the introduction of
policies requiring the registration of summary results
on trial registries as well as the expanded sharing of
participant-level data [11–13].
Internal validity
The protocol contains information that is essential to
appraising internal validity (i.e., risk of bias). It is otherwise
difficult to evaluate and interpret the results of a trial
without access to sufficient information on its design, con-
duct, and analysis. Published final reports often lack
adequate descriptions of important design elements such
as the methods of randomization and blinding [14–18].
Combined with the lack of publicly available protocols,
these deficiencies in published final reports contribute to
the finding that 89% of randomized trials included in
systematic reviews had an ‘unclear’ rating for at least one
domain of the Cochrane risk of bias tool, which is widely
used for evaluating the internal validity of trials [19]. In
contrast, a high-quality protocol is not subject to word
count restrictions and provides a comprehensive view of
the pre-specified study methods.
Selective reporting
Access to a greater level of detail in the protocol also
provides a key mechanism to identify and deter the select-
ive reporting of outcomes and analyses. Unacknowledged
discrepancies in the primary outcomes, sample size calcula-
tions, and analysis plans are often found in published final
reports when compared with the protocol [20–25]. Select-
ive reporting within published reports acts in the same
direction as publication bias of whole trials. Collectively,
these reporting biases tend to inflate the efficacy estimates
of individual trials and meta-analyses.
The protocol can also help to clarify important aspects
of trial organization related to the roles of individuals,
sponsors, and funders in trial design, conduct, and
reporting. Protocols provide information on who con-
trols or owns the trial data, who makes the decision for
early trial stoppage, and the relationship between proto-
col contributors, professional medical writers, and au-
thors of the final study report [26–29]. Protocols will
also often describe any restrictions to the publication of
trial results [26]. This type of information is essential for
adequate assessment of the risk of bias.
External validity
Availability of the protocol facilitates an understanding of
the external validity (i.e., generalizability) of trial results.
To determine how the findings should be applied in prac-
tice to individual patients, it is necessary to evaluate
whether a given clinical scenario differs substantively from
how the trial was conducted. Relevant considerations
include the study setting, selection of trial participants
and centers, details of the interventions and their adminis-
tration, follow-up intensity, and concomitant care [30].
Many of these trial elements are inadequately described in
published final reports.
The protocol, in contrast, conveys much more infor-
mation about these clinically relevant elements. For
example, the eligibility criteria defined in the protocol
are often not fully described in the published final
report, which tends to portray a broader eligible study
population than the protocol [31–33]. Further, the trial
interventions are more completely described in proto-
cols than in the published final reports, which is relevant
when applying the interventions in clinical practice [34].
Complement to trial registries and results databases
While major progress in trial registration has been made
over the past decade, the adherence levels and quality of
registered information are highly variable [22, 35–41].
The Trial Registration Data Set defined by the World
Health Organization and endorsed by the International
Committee of Medical Journal Editors provides a brief
outline of a trial’s topic and design [42]. However, the
methodological information in registries is usually insuf-
ficient to appraise the merits of the study design or iden-
tify selective reporting of analyses [43]. For example, a
recent study of registered and published oncology trials
found that, due to incompletely or inaccurately regis-
tered information, the registry record enabled detection
of only 75% of cases of discrepant primary outcomes in
the published final report compared with using the full
protocol [44]. These limitations of trial registration high-
light the important complementary role of having access
to full protocols.
Challenges and recommendations
Despite its important benefits, public access to protocols
is not yet widespread. Challenges to the routine avail-
ability of high quality trial protocols include the gaps in
incentives and adherence mechanisms, limited venues
for sharing the original and final protocol versions, and
the need for mechanisms to ensure transparent report-
ing and completeness of protocol content. We propose
recommendations to help address each of these chal-
lenges (Table 1).
Adequate incentives
In the absence of a universal adherence mechanism, it is
important to provide sufficient incentives for trial investiga-
tors to share protocols as part of a broader dissemination
plan that includes the full reporting of study results and
participant-level data [1]. Protocol publication provides
credit in the form of a citable paper. Having a protocol that
is open to public vetting also provides a degree of transpar-
ency that can benefit the trial and its investigators by
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boosting public awareness and the perceived trustworthi-
ness of a trial.
Public sharing of protocols should be explicitly recog-
nized by academic institutions and funders as a meritori-
ous component of research performance evaluations.
Rewarding the dissemination of full trial information
helps to recognize its value in reducing research waste
and increasing the impact of a study. There is a growing
movement towards evaluating researchers based on
comprehensive qualitative and quantitative indicators of
impact rather than solely relying on traditional biblio-
metric and funding indices [45–48].
A clear disincentive for protocol sharing is when investi-
gators have signed agreements with sponsors or funders
that inappropriately restrict their freedom to disseminate
the protocol or other essential information related to the
trial [26, 49–51]. It is critical for sponsors, funders, and
investigators to avoid placing such restrictions when
agreeing to collaborate on a trial.
Comprehensive adherence mechanisms
Journal editors, regulators, sponsors, and funders can play
a vital role by implementing policies mandating protocol
availability [1]. Because each stakeholder has a limited
scope of trials within its purview, there is a need for broad
participation across and within all stakeholder groups.
Requiring the submission of protocols to journals along
with manuscripts was suggested (and rejected) as far back
as 1990 [52]. Although most journals still do not routinely
publish trial protocols, some major journals, such as
The BMJ, Lancet, PLoS Medicine, and Annals of
Internal Medicine, have taken the lead by requiring the
submission of protocols and posting them online
alongside trial manuscripts [53–56].
Regulatory authorities also have a critical role. In 2015,
after Gøtzsche and Jørgensen’s pioneering efforts to
obtain access [57], the European Medicines Agency
implemented a policy to grant online access to clinical
study reports (including protocols) that it reviewed as
part of marketing authorization submissions [58]. In the
United States, a recent clarification of the Food and
Drug Administration Amendments Act of 2007 affirmed
the vital role of protocols and required that they be sub-
mitted at the time of registration of summary results on
ClinicalTrials.gov [12]. Although these major advances
have not yet had sufficient time to demonstrate their
impact, a substantial limitation is that almost half of
non-industry sponsored trials fall outside of the scope of
legislative requirements [59]. Legislation in the United
States and European Union excludes phase 1 trials or
those evaluating interventions other than regulated
drugs and devices [12, 58].
Additional key stakeholder groups include industry and
non-industry sponsors and funders. In 2013, the European
Federation of Pharmaceutical Industries and Associations
endorsed the voluntary sharing of trial protocols, results,
and participant-level data for research purposes [60]. An
online industry portal has been established to provide ac-
cess to this information for researchers, subject to approval
of the specific request [61]. However, there is substantial
variability across participating companies in terms of the
scope of disclosure policies as well as the adherence to
them [62, 63]. Some companies, such as GlaxoSmithKline,
have gone further by voluntarily posting a subset of their
protocols on their own publicly accessible website [64].
Since the patchwork of existing editorial, regulatory,
and sponsor policies capture only a fraction of trials
conducted around the world, it is important that journal
editors, regulators, sponsors, and funders implement
measures to improve adherence on a broader scale.
Following the lead of major journals, all journals that
publish a clinical trial report should either post the
protocol as a web supplement or post a link to the on-
line protocol publication. Regulatory policies mandating
public access to protocols should be adopted by govern-
ments as a condition of marketing authorization. Both
industry and non-industry sponsors should make their
protocols available for all trials under their stewardship,
while funders should require protocol sharing as a con-
dition for grant approval.
Table 1 Challenges and recommendations for promoting access to full trial protocols
Challenge Recommendation
Adequate incentives Academic institutions and funders should implement research assessment indicators that give explicit credit to
investigators who share protocols for their ongoing and completed trials
Comprehensive adherence
mechanisms
Journal editors, regulators, sponsors, and funders should implement and enforce policies requiring public sharing
of protocols for all trials within their remit
Prospective access to the
original protocol
The original protocol version receiving ethics approval should be shared or placed in a lockbox prior to participant
enrolment, to be made available at the time of results reporting along with the final protocol version listing any
amendments
Universal venue for sharing
protocols
Trial registries and journals should build capacity to become the standard repositories for housing and publishing
of the original and final protocols online
Complete protocol content Trial protocols should address key elements defined in the SPIRIT (Standard Protocol Items: Recommendations for
Interventional Trials) guidance [2, 67]
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Prospective access to the original protocol
Current journal policies and legislation call for protocol
sharing prior to the completion of data collection or at
the time of results reporting or regulatory submission
[12, 58, 65]. This delayed timing allows the final protocol
version to be shared, including a list of any amendments,
since protocols often evolve with several formal versions
over the course of a trial [66].
However, a major concern is the potential for biased, un-
disclosed amendments to the pre-specified trial outcomes or
analyses based on interim examination of the data. While it
is expected that amendments would be transparently listed
in each protocol version [67], we and others have found that
even revisions to the protocol-defined primary outcomes are
common and not acknowledged in the published final
reports or latest protocol version [20, 22–24, 68, 69].
Public access to both the original protocol version dated
prior to participant enrolment, as well as the final protocol
version with a list of amendments, would provide a verifi-
able record to help identify and evaluate any unacknow-
ledged amendments. Although concerns have been raised
over competitive advantage associated with earlier disclos-
ure of detailed protocol information [70–73], the European
Medicines Agency and legal rulings in the United States
have concluded that very little of the information contained
in a trial protocol constitutes commercially confidential
information that would confer a competitive advantage if
disclosed to other sponsors [74–76]. Earlier protocol shar-
ing helps to assert the intellectual origin of the trial idea.
The originators would have a substantial head start with
funding, ethics approval, and logistical implementation of
the trial. Further, the basic trial description should already
be publicly documented on a trial registry prior to partici-
pant enrolment. The widespread adoption of trial registra-
tion policies reflects broad acceptance that the benefits of
public access outweigh the potential risks.
In rare cases where legitimate concerns remain about
prospectively sharing the full protocol prior to trial incep-
tion, a potential solution would be to offer a lockbox
whereby the original protocol receiving ethics approval is
submitted to a registry or journal prior to participant
enrolment, but not made publicly available until a later
time prior to data unblinding. For example, in the context
of certain trials evaluating complex interventions where
participants are blinded to the true nature of the placebo
arm or study hypotheses, a lockbox can help to address
concerns about unblinding when participants have access
to the protocol while the trial is ongoing [77].
Universal venue for sharing protocols
Trial registries already provide an established, unre-
stricted, searchable online mechanism for recording basic
protocol information for a trial. A natural extension of this
important role would be for registries to serve as the
standard repository for housing the original and final trial
protocols alongside each registry record. ClinicalTrials.gov
and the Australian New Zealand Clinical Trials Registry
have recently allowed the full protocol and related docu-
ments to be uploaded [12, 78]. To ensure that protocols
are captured for all trials regardless of where they are
registered, it is important to build protocol uploading cap-
acity for all registries in the World Health Organization
Registry Network.
Another key venue for protocol dissemination is jour-
nals. Protocol publication offers citable indexing in Med-
line or other bibliographic databases. There is also the
opportunity for additional explanation and discussion of
topical issues, beyond the protocol text. However, it is
usually not possible to implement major design modifi-
cations in response to peer reviewer comments, given
that the protocol has already been approved by a re-
search ethics committee, funder, or regulator. Another
limitation is that the protocol published in journals is
often an abbreviated version of the original protocol,
which can reduce transparency if the published version
omits relevant details about the trial. Further, given the
small number of journals that currently publish proto-
cols, there would be limited capacity to efficiently handle
the potential volume of protocol submissions for the
thousands of trials initiated monthly [79].
As protocol publication becomes more widespread, it
will be important for journals to commit the necessary
resources to review and make decisions on submissions
in a timely manner. Journals that publish abridged ver-
sions of trial protocols should include the full protocol
as an online appendix (for example, see [80]), similar to
how some journals post the full protocol alongside the
final report of trial results. After trial completion, the
final protocol version could also be posted as a supple-
mentary appendix to the original published protocol.
Complete protocol content
The sharing of a protocol is only useful if the document
adequately details the key features of a trial. Protocols
are usually more informative about study design and
organization than published trial reports, but many pro-
tocols still lack information about important methodo-
logical, ethical, and administrative trial elements [2].
Missing or unclear information in the protocol makes it
difficult to know whether or not the issues were ad-
equately handled by the trial investigators. Poor quality
protocols also lead to increased time and costs required
for trial completion [66].
To help promote high-quality and complete content,
protocols should adhere to the SPIRIT (Standard Protocol
Items: Recommendations for Interventional Trials) 2013
Statement and explanatory paper, which define a mini-
mum checklist of items to address [2, 67, 81]. SPIRIT has
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been endorsed internationally by over 100 medical jour-
nals, including Trials [65], as well as research organiza-
tions and funders. An online, SPIRIT-based protocol
authoring tool is being developed to make it easier to
create, manage, and register high-quality protocols [82].
Conclusions
Ensuring public access to protocols adds considerable
value and reduces research waste by providing important
study details that are often not found in other sources of
information. The routine sharing of protocols with pre-
defined outcomes and analysis plans is a simple, low cost,
and feasible way to deter and identify selective reporting.
However, key challenges must be addressed to fully realize
the positive impact of protocol availability. With ongoing
and expanded support from journal editors, trial registries,
sponsors, funders, regulators, and legislators, public access
to study protocols can become standard practice for the
benefit of patients and other users of evidence from
clinical trials.
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